Trodelv IV infusion 200mg (Sacituzumab govitecan), manufactured by Gilead Science (YJ code: 4291472D1026, standard: 200mg bottle), is a Trop-2-directed antibody-drug conjugate used to treat certain metastatic breast cancers and metastatic urothelial cancer. This targeted therapy works by delivering an anticancer drug directly to cancer cells that express the Trop-2 protein.
Trodelv IV infusion 200mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →